To hear about similar clinical trials, please enter your email below
Trial Title:
Hypercoagulable Parameters as Predictors of Thrombotic Events and Prognosis in Patients With Advanced Non-Small Cell Lung Carcinoma
NCT ID:
NCT00192829
Condition:
Non-Small Cell Lung Carcinoma
Venous Thromboembolism
Conditions: Official terms:
Carcinoma
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Thromboembolism
Venous Thromboembolism
Thrombophilia
Conditions: Keywords:
Lung cancer
Thrombosis
Hypercoagulable
Study type:
Observational
Overall status:
Unknown status
Study design:
Time perspective:
Prospective
Intervention:
Intervention type:
Procedure
Intervention name:
Blood sample withdrawal
Summary:
The association between cancer and thrombosis is well known and the occurrence of
thrombotic complications is commonly associated with poor prognosis. The aim os this
study is to determine the possible value of hypercoagulable parameters as prognostic
parameters in advanced non-small cell lung carcinoma (NSCLC).
Criteria for eligibility:
Criteria:
Inclusion Criteria:
- Histologically or cytologically confirmed diagnosis of NSCLC.
- normal serum bilirubin
- informed concent to participate in the study
Exclusion Criteria:
- anticoagulant therapy
- infectious disease
Gender:
All
Minimum age:
N/A
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Hematology Laboratory
Address:
City:
Haifa
Country:
Israel
Status:
Recruiting
Contact:
Last name:
Galit Sarig, Ph.D
Phone:
+972-4-8543523
Email:
g_sarig@rambam.health.gov.il
Investigator:
Last name:
Galit Sarig, Ph.D
Email:
Principal Investigator
Facility:
Name:
Oncology Institution, Rambam Health Campus
Address:
City:
Haifa
Country:
Israel
Status:
Recruiting
Contact:
Last name:
Nissim Haim, M.D
Email:
n_haim@rambam.health.gov.il
Investigator:
Last name:
Nissim Haim, M.D
Email:
Principal Investigator
Start date:
June 2005
Lead sponsor:
Agency:
Rambam Health Care Campus
Agency class:
Other
Source:
Rambam Health Care Campus
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT00192829
